Menopause Perspectives and Treatment of Asian Women

ABSTRACT

This review summarizes the published literature on menopausal symptoms and concerns from the perspective of Asian menopausal women, compares and contrasts common menopausal symptoms between the Asian and the Western postmenopausal populations, and highlights considerations from the perspective of clinical practice. In contrast to menopausal symptomatology described in the Western populations, musculoskeletal symptoms and sleeplessness, rather than vasomotor symptoms, dominate the clinical presentation in menopausal Asian women; decreased sexual function, although an important issue, is not commonly brought up for discussion in the context of bothersome menopausal symptoms by Asian women. The epidemiology of the common disorders of aging, such as osteoporosis, breast cancer, and cardiovascular disease, differs between the Asian and Western populations. Awareness and the use of hormone replacement therapy (HRT) are generally low and noted to vary significantly among populations from different Asian countries. The perspectives, and the spectrum of symptom burden relating to reproductive aging in the Asian menopausal women are unique; an appreciation of these distinctions will allow for better tailoring of management paradigms to accommodate the diversified cultural, customary, and religious backgrounds and the socioeconomic disparities that exist among the various Asian populations.

KEYWORDS

Asian women - menopause - perspectives - symptoms - treatment

REFERENCES

• 1 Freeman E W, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review.  Climacteric. 2007;  10(3) 197-214
• 2 Ho S C, Chan S G, Yip Y B, Cheng A, Yi Q, Chan C. Menopausal symptoms and symptom clustering in Chinese women.  Maturitas. 1999;  33(3) 219-227
• 3 Pan H-A, Wu M-H, Hsu C C, Yao B L, Huang K E. The perception of menopause among women in Taiwan.  Maturitas. 2002;  41(4) 269-274
• 4 Chang C, Chang C H. Menopause and hormone using experiences of Chinese women in Taiwan.  Health Care Women Int. 1996;  17(4) 307-318
• 5 Chim H, Tan B HI, Ang C C, Chew E MD, Chong Y S, Saw S M. The prevalence of menopausal symptoms in a community in Singapore.  Maturitas. 2002;  41(4) 275-282
• 6 Tan D, Darmasetiawan S, Haines C J Expert Panel on Menopause in Asian Women et al. Guidelines for hormone replacement therapy of Asian women during the menopausal transition and thereafter.  Climacteric. 2006;  9(2) 146-151
• 7 Asia Pacific Menopause Federation .Asia-Pacific Menopause Federation consensus statement on the management of the menopause; April 2008. http://Available at: www.apmf.net Accessed June 3, 2010
• 8 Haines C J, Xing S M, Park K-H, Holinka C F, Ausmanas M K. Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study.  Maturitas. 2005;  52(3–4) 264-276
• 9 Taechakraichana N, Holinka C F, Haines C J, Subramaniam R, Tian X W, Ausmanas M K. Distinct lipid/lipoprotein profiles and hormonal responsiveness in nine ethnic groups of postmenopausal Asian women: the Pan-Asia Menopause (PAM) study.  Climacteric. 2007;  10(3) 225-237
• 10 Limpaphayom K K, Darmasetiawan M S, Hussain R I, Burriss S W, Holinka C F, Ausmanas M K. Differential prevalence of quality-of-life categories (domains) in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study.  Climacteric. 2006;  9(3) 204-214
• 11 Huang K-E, Xu L, I N N, Jaisamrarn U. The Asian Menopause Survey: knowledge, perceptions, hormone treatment and sexual function.  Maturitas. 2010;  65(3) 276-283
• 12 Genazzani A R, Schneider H P, Panay N, Nijland E A. The European Menopause Survey 2005: women's perceptions on the menopause and postmenopausal hormone therapy.  Gynecol Endocrinol. 2006;  22(7) 369-375
• 13 Huang K-E, Baber R. Updated clinical recommendations for the use of tibolone in Asian women.  Climacteric. 2010;  , May 5 (Epub ahead of print)
• 14 Haines C J, Rong L, Chung T KH, Leung D HY. The perception of the menopause and the climacteric among women in Hong Kong and southern China.  Prev Med. 1995;  24(3) 245-248
• 15 Lock M, Kaufert P, Gilbert P. Cultural construction of the menopausal syndrome: the Japanese case.  Maturitas. 1988;  10(4) 317-332
• 16 Obermeyer C M. Menopause across cultures: a review of the evidence.  Menopause. 2000;  7(3) 184-192
• 17 Sukwatana P, Meekhangvan J, Tamrongterakul T, Tanapat Y, Asavarait S, Boonjitrpimon P. Menopausal symptoms among Thai women in Bangkok.  Maturitas. 1991;  13(3) 217-228
• 18 Chaikittisilpa S, Limpaphayom K, Chompootweep S, Taechakraichana N. Symptoms and problems of menopausal women in Klong Toey slum.  J Med Assoc Thai. 1997;  80(4) 257-261
• 19 Zhao G, Wang L, Yan R, Dennerstein L. Menopausal symptoms: experience of Chinese women.  Climacteric. 2000;  3(2) 135-144
• 20 Punyahotra S, Dennerstein L, Lehert P. Menopausal experiences of Thai women. Part 1: Symptoms and their correlates.  Maturitas. 1997;  26(1) 1-7
• 21 Wasti S, Robinson S C, Akhtar Y, Khan S, Badaruddin N. Characteristics of menopause in three socioeconomic urban groups in Karachi, Pakistan.  Maturitas. 1993;  16(1) 61-69
• 22 Rossouw J E, Anderson G L, Prentice R L Writing Group for the Women's Health Initiative Investigators et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.  JAMA. 2002;  288(3) 321-333
• 23 Anderson G L, Limacher M, Assaf A R Women's Health Initiative Steering Committee et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.  JAMA. 2004;  291(14) 1701-1712
• 24 Naftolin F, Schneider H PG, Sturdee D W Executive Committee of the International Menopause Society et al. Guidelines for hormone treatment of women in the menopausal transition and beyond.  Climacteric. 2004;  7(4) 333-337
• 25 Skouby S O, Al-Azzawi F, Barlow D European Menopause and Andropause Society et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy.  Maturitas. 2005;  51(1) 8-14
• 26 North American Menopause Society . Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of the North American Menopause Society.  Menopause. 2004;  11(6 Pt 1) 589-600
• 27 Redactor G. Posición Latinamericana en relación con el estado actual de la terapia hormonal.  Ginecol Obstet Mex. 2005;  73 205-211
• 28 Pines A, Sturdee D W, Birkhauser M H, Schneider H PG, Gambacciani M, Panay N. for the Board of the International Menopause Society . IMS updated recommendation on postmenopausal hormone therapy.  Climacteric. 2007;  10 181-194
• 29 Utian W H, Shoupe D, Bachmann G, Pinkerton J V, Pickar J H. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.  Fertil Steril. 2001;  75(6) 1065-1079
• 30 Nijland E A, Weijmar Schultz W C, Nathorst-Boös J LISA study investigators et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in natural menopausal women: results of a randomized active-controlled trial.  J Sex Med. 2008;  5 646-656
• 31 Hammar M L, van de Weijer P, Franke H R, Pornel B, von Mauw E M, Nijland E A. Total Study Investigators Group . Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.  Br J Obstet Gynaecol. 2007;  114 1522-1529
• 32 Pan H A, Wang S T, Pai M C, Chen C H, Wu M H, Huang K E. Cognitive function variations in postmenopausal women treated with continuous, combined HRT or tibolone. A comparison.  J Reprod Med. 2003;  48(5) 375-380
• 33 Wu M H, Pan H A, Wang S T, Hsu C C, Chang F M, Huang K E. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy.  Climacteric. 2001;  4(4) 314-319
• 34 Yang T S, Tsan S H, Chen C R, Chang S P, Yuan C C. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women.  Zhonghua Yi Xue Za Zhi (Taipei). 1999;  62(5) 308-315
• 35 Lam P M, Cheung G W, Shek D T, Lee D T, Haines C J, Chung T K. A randomized, placebo-controlled, crossover study of tibolone (Livial) on menopause symptoms, psychological well-being, and dyadic relationship of postmenopausal Chinese women and their spouses.  Menopause. 2004;  11(4) 416-422
• 36 Koh K K, Ahn J Y, Jin D K et al. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study.  Arterioscler Thromb Vasc Biol. 2003;  23(10) 1889-1894
• 37 Lee K B, Lee J M, Yoon J H, Park C Y. The safety of tibolone in epithelial ovarian cancer patients.  Maturitas. 2006;  55(2) 156-161
• 38 Cummings S R, Ettinger B, Delmas P D LIFT Trial Investigators et al. The effects of tibolone in older postmenopausal women.  N Engl J Med. 2008;  359(7) 697-708
• 39 White R H, Keenan C R. Effects of race and ethnicity on the incidence of venous thromboembolism.  Thromb Res. 2009;  123(Suppl 4) S11-S17
• 40 Tan K S, Rashid A, Tan C T. Venous thromboembolism in ischemic stroke in Asia.  Neurology Asia. 2008;  13 95-101
• 41 Valdivia I, Campodónico I, Tapia A, Capetillo M, Espinoza A, Lavín P. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women.  Fertil Steril. 2004;  81(3) 617-623
• 42 Bruce D, Robinson J, McWilliams S, Reddy M, Fentiman I, Rymer J. Long-term effects of tibolone on mammographic density.  Fertil Steril. 2004;  82(5) 1343-1347
• 43 Krebs E E, Ensrud K E, MacDonald R, Wilt T J. Phytoestrogens for treatment of menopausal symptoms: a systematic review.  Obstet Gynecol. 2004;  104(4) 824-836
• 44 Geller S E, Studee L. Soy and red clover for mid-life and aging.  Climacteric. 2006;  9(4) 245-263
• 45 Liu H, Yang D N. Clinical observations on treatment of 86 peri-climacteric syndrome cases by point cutgut embedding.  Shanghai J Acupunct Mox. 2007;  26 5-7
• 46 Zhou J, Qin Z Y, Li W L et al. Clinical observation on therapeutic effect of electroacupuncture at Sanyinjiao (SP 6) on peri-menopausal syndrome [in Chinese].  Zhongguo Zhen Jiu. 2006;  26(9) 617-620
• 47 Cho S-H, Whang W-W. Acupuncture for vasomotor menopausal symptoms: a systematic review.  Menopause. 2009;  16(5) 1065-1073
• 48 Chow L. Breast cancer incidence rising in Asian women at younger age: Sunitinib shows potential as treatment for metastatic disease.  First Asian Breast Cancer Conference November 22, 2009 New Delhi, India;
• 49 Chang K-J, Kuo W-H, Wang M-Y. The epidemiology of breast cancer in Taiwan [in Chinese with English abstract].  J Oncol Soc. 2008;  24 85-93
• 50 Ravdin P M, Cronin K A, Howlader N et al. The decrease in breast-cancer incidence in 2003 in the United States.  N Engl J Med. 2007;  356(16) 1670-1674
• 51 Greendale G A, Reboussin B A, Sie A Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density.  Ann Intern Med. 1999;  130(4 Pt 1) 262-269
• 52 Habel L A, Capra A M, Oestreicher N et al. Mammographic density in a multiethnic cohort.  Menopause. 2007;  14(5) 891-899
• 53 Grodstein F, Manson J E, Stampfer M J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation.  J Womens Health (Larchmt). 2006;  15(1) 35-44